173 related articles for article (PubMed ID: 27118109)
1. Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.
Pettengell R; Sebban C; Zinzani PL; Derigs HG; Kravchenko S; Singer JW; Theocharous P; Wang L; Pavlyuk M; Makhloufi KM; Coiffier B
Br J Haematol; 2016 Sep; 174(5):692-9. PubMed ID: 27118109
[TBL] [Abstract][Full Text] [Related]
2. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
Pettengell R; Coiffier B; Narayanan G; de Mendoza FH; Digumarti R; Gomez H; Zinzani PL; Schiller G; Rizzieri D; Boland G; Cernohous P; Wang L; Kuepfer C; Gorbatchevsky I; Singer JW
Lancet Oncol; 2012 Jul; 13(7):696-706. PubMed ID: 22652183
[TBL] [Abstract][Full Text] [Related]
3. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
[TBL] [Abstract][Full Text] [Related]
4. Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
Heyman B; Rizzieri D; Adams DJ; De Castro C; Diehl L; Li Z; Moore J; Beaven A
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):679-686. PubMed ID: 30166257
[TBL] [Abstract][Full Text] [Related]
5. Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.
Keating GM
Drugs; 2016 Oct; 76(16):1579-1586. PubMed ID: 27757832
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial.
Pettengell R; Coiffier B; Egorov A; Singer J; Sivcheva L
Clin Drug Investig; 2018 Jun; 38(6):527-533. PubMed ID: 29564722
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.
Sancho JM; Navarro B; Soler Campos JA; de Oteyza JP; de Barrenetxea Lekue C; Bregni M; Grasso Cicala S; Spione M; Mombiedro C; Soler B; Zinzani PL
Eur J Haematol; 2020 May; 104(5):499-508. PubMed ID: 31997425
[TBL] [Abstract][Full Text] [Related]
8. Pixantrone beyond monotherapy: a review.
Barrenetxea Lekue C; Grasso Cicala S; Leppä S; Stauffer Larsen T; Herráez Rodríguez S; Alonso Caballero C; Jørgensen JM; Toldbod H; Leal Martínez I; D'Amore F
Ann Hematol; 2019 Sep; 98(9):2025-2033. PubMed ID: 31312929
[TBL] [Abstract][Full Text] [Related]
9. Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.
Eyre TA; Linton KM; Rohman P; Kothari J; Cwynarski K; Ardeshna K; Bailey C; Osborne WL; Rowntree C; Eden D; Shankara P; Eyre DW; Jasani P; Chaidos A; Collins GP; Hatton CS
Br J Haematol; 2016 Jun; 173(6):896-904. PubMed ID: 26956150
[TBL] [Abstract][Full Text] [Related]
10. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
Srokowski TP; Liebmann JE; Modiano MR; Cohen GI; Pro B; Romaguera JE; Kuepfer C; Singer JW; Fayad LE
Cancer; 2011 Nov; 117(22):5067-73. PubMed ID: 21681734
[TBL] [Abstract][Full Text] [Related]
11. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
Tobinai K; Igarashi T; Itoh K; Kurosawa M; Nagai H; Hiraoka A; Kinoshita T; Uike N; Ogura M; Nawano S; Mori S; Ohashi Y;
Cancer Sci; 2011 Sep; 102(9):1698-705. PubMed ID: 21645173
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.
Lim ST; Fayad L; Tulpule A; Modiano M; Cabanillas F; Laffranchi B; Allievi C; Bernareggi A; Levine AM
Leuk Lymphoma; 2007 Feb; 48(2):374-80. PubMed ID: 17325899
[TBL] [Abstract][Full Text] [Related]
13. Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.
Belada D; Georgiev P; Dakhil S; Inhorn LF; Andorsky D; Beck JT; Quick D; Pettengell R; Daly R; Dean JP; Pavlyuk M; Failloux N; Hübel K
Future Oncol; 2016 Aug; 12(15):1759-68. PubMed ID: 27093976
[TBL] [Abstract][Full Text] [Related]
14. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
[TBL] [Abstract][Full Text] [Related]
15. Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306).
Pettengell R; Długosz-Danecka M; Andorsky D; Belada D; Georgiev P; Quick D; Singer JW; Singh SB; Pallis A; Egorov A; Salles G
Br J Haematol; 2020 Jan; 188(2):240-248. PubMed ID: 31879945
[TBL] [Abstract][Full Text] [Related]
16. Pixantrone maleate for non-Hodgkin's lymphoma.
Mukherji D; Pettengell R
Drugs Today (Barc); 2009 Nov; 45(11):797-805. PubMed ID: 20126672
[TBL] [Abstract][Full Text] [Related]
17. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma.
Lignon J; Sibon D; Madelaine I; Brice P; Franchi P; Briere J; Mounier N; Gisselbrecht C; Faure P; Thieblemont C
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):262-9. PubMed ID: 20709662
[TBL] [Abstract][Full Text] [Related]
18. The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use.
Péan E; Flores B; Hudson I; Sjöberg J; Dunder K; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
Oncologist; 2013; 18(5):625-33. PubMed ID: 23615696
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.
Goy A; Forero A; Wagner-Johnston N; Christopher Ehmann W; Tsai M; Hatake K; Ananthakrishnan R; Volkert A; Vandendries E; Ogura M
Br J Haematol; 2016 Aug; 174(4):571-81. PubMed ID: 27101934
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]